Evidence map›Paper›PMID 22544320›Full record

ArticleCell cycle (Georgetown, Tex.)2012

Expanding applications of chemical genetics in signal transduction.

Scott M Carlson, Forest M White

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Scott M CarlsonDepartment of Biological Engineering; Massachusetts Institute of Technology; Cambridge, MA, USA.
Forest M White

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Tumor Cell Networks CenterU54CA112967 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A · 2004 to 2015
$26.2M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LEVINE, STUART S · 1985 to 2020
$25.6M
PHOSPHOTYROSYL PROTEINS IN INSULIN RECEPTOR SIGNALINGR01DK042816 · NIDDK · DARTMOUTH COLLEGE · PI LIENHARD, GUSTAV E. · 1990 to 2008
$3.9M
Quantitative Analysis of Epidermal Growth Factor Receptor Signaling NetworksR01CA118705 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WHITE, FOREST M · 2008 to 2012
$1.8M
NCI NIH HHS 5P30CA014051NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA118705NCI NIH HHS R01CA118705NCI NIH HHS U54 CA112967NCI NIH HHS U54CA112967NIDDK NIH HHS R01 DK042816NIDDK NIH HHS R01DK42816NIEHS NIH HHS P30 ES002109
6 · The paper itself

Abstract

Chemical genetics represents an expanding collection of techniques applied to a variety of signaling processes. These techniques use a combination of chemical reporters and protein engineering to identify targets of a signaling enzyme in a global and non-directed manner without resorting to hypothesis-driven candidate approaches. In the last year, chemical genetics has been applied to a variety of kinases, revealing a much broader spectrum of substrates than had been appreciated. Here, we discuss recent developments in chemical genetics, including insights from our own proteomic screen for substrates of the kinase ERK2. These studies have revealed that many kinases have overlapping substrate specificity, and they often target several proteins in any particular downstream pathway. It remains to be determined whether this configuration exists to provide redundant control, or whether each target contributes a fraction of the total regulatory effect. From a general perspective, chemical genetics is applicable in principle to a broad range of posttranslational modifications (PTMs), most notably methylation and acetylation, although many challenges remain in implementing this approach. Recent developments in chemical reporters and protein engineering suggest that chemical genetics will soon be a powerful tool for mapping signal transduction through these and other PTMs.

Indexed as

PharmacogeneticsSignal TransductionAcetylationHeLa CellsHumansMethylationMitogen-Activated Protein Kinase 1PhosphorylationProtein EngineeringProtein Processing, Post-TranslationalProteinsProteomicsSubstrate SpecificityMitogen-Activated Protein Kinase 1Proteins

Identifiers

PMID22544320
PMCPMC3359120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.